32
nanotimes
10-02 :: February 2010
Companies
Facts
second quarter and six months ended December 31, development of non-Iluvien product candidates
2009. The Company reported a consolidated net through our ongoing collaboration agreement with
loss of $24,000, or $0.00 per share for the quarter Pfizer, Inc. and through the application our BioSili-
ended December 31, 2009, compared to a consoli- con technology. We are excited by the opportunities
dated net loss of $870,000, or $0.05 per share, for in our product pipeline” Dr. Paul Ashton, President
the quarter ended December 31, 2008. Revenues and CEO of pSivida.
totaled $3.4 million for the three months ended

http://www.psivida.com
December 31, 2009 compared to revenues of $2.9
million for the three months ended December 31,
2008. Cash and cash equivalents totaled approxima- P
VA TEPLA (TPE), Germany, specialized in high-
temperature vacuum systems and crystal-growing
tely $5.1 million at December 31, 2009, a decrease systems, has received an order for supply of around
of $834,000 compared to approximately $6.0 million 50 crystal-growing systems for the production of mo-
at September 30, 2009. nocrystalline silicon ingots. The new customer is one
of China‘s leading solar module manufacturers for
For the six months ended December 31, 2009, the global photovoltaic market. The two companies
the Company reported a consolidated net loss of are planning a long-term cooperation. The systems
$1.6 million, or $0.09 per share, compared to a will be delivered by the end of June 2010.
consolidated net loss of $1.3 million, or $0.07 per
share, for the six months ended December 31, 2008. The Company has published further its preliminary
Revenues for the six months ended December 31, consolidated figures for fiscal year 2009. Consoli-
2009 were $6.8 million compared to revenues of dated sales revenues were EUR135 million (previous
$5.8 million for the six months ended December 31, year: EUR168.6 million). Incoming orders decrea-
2008. sed from EUR189.9 million in the previous year to
EUR69 million in 2009. As of December 31, 2009,
“Commencing April 2010, the annual interest rate the order backlog amounted to EUR87 million (previ-
on our $15 million conditional note from Alimera ous year: EUR151.8 million). The decrease in busi-
increases to 20% and monthly principal payments of ness volume as compared with 2008 is due to the
$500,000 are scheduled to begin,” said Dr Ashton. economic and financial crisis, which led to a plunge
“The occurrence of certain Alimera liquidity events, in capital expenditure in PVA TePla‘s key sales mar-
such as an acquisition or IPO generating over $75m kets. Consolidated sales revenues were below the
in gross proceeds, would accelerate payment of the forecasted figure due to delivery extensions to 2010
note. In addition, FDA approval of Iluvien™ would requested by customers.
trigger a $25 million milestone from Alimera and,

http://www.pvatepla.com
once commercialized, pSivida would be entitled to
receive 20% of any Iluvien™ profits,” explained Dr.
Paul Ashton, President and CEO of pSivida. T
he Quantum Light™ Optic from QD Vision was
named a finalist in the 2010 Edison Best New
“Beyond the Iluvien™ trials, we are advancing the Product Awards. The Quantum Light™ Optic, from